A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
| 対象疾患 | Major Depressive Disorder, Depression |
|---|---|
| 相 | 第3相 |
| スポンサー | Levomecor Inc. |
| ステータス | 早期終了 |
| 参加者数 | 236 名 |
| 介入（薬剤） | REL-1017 |
| 開始日 | 2021年3月30日 |
| 完了日 | 2024年12月31日 |
| 結果公開日 | 2026年7月10日 |
概要
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.
Change From Baseline to Day 28 in MADRS Total Score
| REL-1017 | -14.81 ± 1.00 Scores on a scale (MADRS10) |
|---|---|
| Placebo | -13.9 ± 1.01 Scores on a scale (MADRS10) |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital
- Individualized Functional Connectivity Targeting in aiTBS for Depression — Brigham and Women's Hospital